Balance Sheet
Cash Flow Statement
Beginning Cash BalanceGains from Sales and Divestitures
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Cash from Financing Activities: 2012-2022

Historic Cash from Financing Activities for RedHill Biopharma (RDHL) over the last 10 years, with Dec 2022 value amounting to $7.2 million.

  • RedHill Biopharma's Cash from Financing Activities fell 59.02% to $7.2 million in Q4 2022 from the same period last year, while for Dec 2022 it was $11.5 million, marking a year-over-year decrease of 84.41%. This contributed to the annual value of $8.4 million for FY2024, which is 60.74% down from last year.
  • As of Q4 2022, RedHill Biopharma's Cash from Financing Activities stood at $7.2 million, which was up 225.87% from -$5.7 million recorded in Q3 2022.
  • In the past 5 years, RedHill Biopharma's Cash from Financing Activities registered a high of $59.1 million during Q1 2020, and its lowest value of -$5.7 million during Q3 2022.
  • In the last 3 years, RedHill Biopharma's Cash from Financing Activities had a median value of $7.6 million in 2020 and averaged $14.1 million.
  • As far as peak fluctuations go, RedHill Biopharma's Cash from Financing Activities skyrocketed by 78,406.67% in 2018, and later crashed by 472.67% in 2022.
  • Over the past 5 years, RedHill Biopharma's Cash from Financing Activities (Quarterly) stood at $18.4 million in 2018, then surged by 96.67% to $36.1 million in 2019, then tumbled by 78.00% to $7.9 million in 2020, then spiked by 121.25% to $17.6 million in 2021, then crashed by 59.02% to $7.2 million in 2022.
  • Its last three reported values are $7.2 million in Q4 2022, -$5.7 million for Q3 2022, and $14.9 million during Q2 2022.